SCHEMBL22474029

SCHEMBL22474029

Cc1nncn1C1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 1/20 0.38
PIK3CD O00329 3/20 0.37
PIK3CA P42336 3/20 0.37
PIK3CB P42338 3/20 0.37
PIK3CG P48736 3/20 0.37
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
MAP3K5 Q99683 4/20 0.34
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
MAPK1 P28482 2/20 0.32
RORC P51449 2/20 0.31
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE1C Q14123 1/20 0.31
CTSE P14091 1/20 0.31
BACE1 P56817 1/20 0.31
POLB P06746 1/20 0.31
KMT2A Q03164 1/20 0.31
PRKDC P78527 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18912008 0.86
SCHEMBL22474026 0.82 MEN1 (0.37) HCAR1JAK2JAK1RORCKMT2A
SCHEMBL22474028 0.81 PI4KA (0.37) HCAR1JAK2JAK1KMT2A
SCHEMBL16906236 0.78 ALOX15 (0.40) PIK3CDPIK3CAPIK3CBPIK3CGJAK1
SCHEMBL21783964 0.77 HCAR1 (0.35) HCAR1JAK1MAP3K5GSK3BDYRK1A
SCHEMBL17008858 0.71 HCAR1 (0.42) HCAR1PIK3CDPIK3CAGSK3BDYRK1A
SCHEMBL18322749 0.70 HCAR1 (0.38) HCAR1PIK3CAJAK2JAK1GSK3B
SCHEMBL25100302 0.69 MAP3K5 (0.50) MAP3K5
SCHEMBL22474083 0.69 MAP3K5 (0.53) MAP3K5
SCHEMBL30232772 0.69 MAP3K5 (0.50) MAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3572401-B1 ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) 2021-09-29 EP disclosed
US-10787435-B2 ASK1 inhibitor and preparation method and use thereof Fuijan Cosunter Pharmaceutical Co. Ltd. (CN) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787435-B2 ASK1 inhibitor and preparation method and use thereof MARK1, MAP3K1, MAP3K20 HCAR1 3489/4885PIK3CD 1903/4885PIK3CA 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.